29 Feb Beyond-Use Dates: Ready or Not, USP Guidelines Will Impact Your Practice
As featured in dvm360 Magazine, February 2024 Issue By Melissa King, PharmD, Director of Manufacturing Operations, Epicur Pharma and Andrew Filewicz, PharmD, Director of Pharmacy Compounding, Stokes Pharmacy February, 29 2024— New revisions to the United States Pharmacopeia (USP) Chapter 795, for compounding of non-sterile pharmaceuticals, and Chapter 797, for compounding sterile preparations, are in effect. These standards of practice can now be enforced by the FDA, local state boards of pharmacy, and accreditation organizations. The new USP guidelines limit the ability of 503A compounding pharmacies to extend Beyond-Use Dates (BUDs). This regulatory...